Complete Response to the Combination of Immunotherapy and Targeted Therapy in Stage IV Nasal Adenocarcinoma of a Dog: A Case Report. [PDF]
Vet Med SciThe combination therapy of anti‐PD‐1 and TOC showed good therapeutic effects in this case of canine nasal adenocarcinoma, underscoring the potential of combining immunotherapy with targeted therapy in cases where single‐agent treatments fail. Combination therapy may enhance tumour growth inhibition by regulating the tumour immune microenvironment.
Hu Y +6 more
europepmc +2 more sources
Evaluation of the efficacy and tolerance of pamidronate in complex regional pain syndrom type 1. [PDF]
Sci RepThis study aimed to determine whether the delay between symptom onset and treatment initiation, the dose of pamidronate, and bone mineral density (BMD) influence the response to pamidronate treatment in complex regional pain syndrome type 1 (CRPS 1).
Doussiere M +7 more
europepmc +2 more sources
Clinical efficacy and safety of pamidronate therapy on bone mass density in early post-renal transplant period: a meta-analysis of randomized controlled trials. [PDF]
PLoS ONE, 2014 INTRODUCTION: The overall effect of pamidronate on bone mass density (BMD) in the early renal transplant period varies considerably among studies. The effects of pamidronate on graft function have not been determined.
Zijie Wang +10 more
doaj +1 more source
Advanced Platelet-Rich Fibrin in Surgical Management of Medication-Related Osteonecrosis of the Jaw: A Prospective Case Series Study. [PDF]
Clin Exp Dent ResAbstract Background Medication‐related osteonecrosis of the jaw (MRONJ) is a severe complication associated with antiresorptive or antiangiogenic therapy. Surgical debridement is the mainstay of treatment for moderate to advanced disease, while adjunctive regenerative approaches such as advanced platelet‐rich fibrin (A‐PRF) may enhance soft tissue ...
Hajdari B +5 more
europepmc +2 more sources
Genotype-phenotype correlations and long-term efficacy of pamidronate therapy in patients with osteogenesis imperfecta [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2022 Purpose Osteogenesis imperfecta (OI) is a rare bone fragility disorder caused by defects in type 1 collagen biosynthesis. This study investigated the genotype-phenotype correlations and the efficacy of pamidronate therapy in patients with OI in a single ...
Yunha Choi +5 more
doaj +1 more source
The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice. [PDF]
PLoS ONE, 2015 A novel avian influenza virus H7N9 infection occurred among human populations since 2013. Although the lack of sustained human-to-human transmission limited the epidemics caused by H7N9, the late presentation of most patients and the emergence of ...
Jian Zheng +14 more
doaj +1 more source
Pediatric Rheumatology Online Journal, 2009 Background Chronic recurrent multifocal osteomyelitis (CRMO) is an inflammatory, non-infectious osteopathy that affects predominantly patients ≤ 18 years of age. There is no uniformly effective treatment.
Reslan Walid +5 more
doaj +1 more source
Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2021 Purpose Osteoporosis is a skeletal disorder characterized by reduced bone mass that results in increased risk of fractures. Pediatric osteoporosis can be caused by monogenic diseases, chronic diseases, and/or their treatment.
Ji-Hee Yoon +4 more
doaj +1 more source
BMC Musculoskeletal Disorders, 2009 Background In case of contraindications or intolerance during treatment with oral bisphosphonates (OB), administration of pamidronate intravenously is a widely used alternative. In this study we compared the effect on change in bone mineral density (BMD)
Dijkmans Ben AC +5 more
doaj +1 more source
The effect of low-dose intravenous bisphosphonate treatment on osteoporosis in children with quadriplegic cerebral palsy [PDF]
Korean Journal of Pediatrics, 2017 PurposeQuadriplegic children with cerebral palsy are more susceptible to osteoporosis because of various risk factors that interfere with bone metabolism. Pamidronate is effective for pediatric osteoporosis, but there are no guidelines for optimal dosage
Soon Jeong Moon +4 more
doaj +1 more source